Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ultragenyx Pharmaceutical (RARE) Gross Margin: 2016-2025

Historic Gross Margin for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Sep 2025 value amounting to 82.50%.

  • Ultragenyx Pharmaceutical's Gross Margin fell 243.00% to 82.50% in Q3 2025 from the same period last year, while for Sep 2025 it was 84.69%, marking a year-over-year decrease of 156.00%. This contributed to the annual value of 86.30% for FY2024, which is 328.00% down from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Gross Margin is 82.50%, which was down 4.28% from 86.18% recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Gross Margin high stood at 96.39% for Q2 2021, and its period low was 79.42% during Q1 2025.
  • Moreover, its 3-year median value for Gross Margin was 86.18% (2025), whereas its average is 86.38%.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Gross Margin skyrocketed by 443bps in 2021 and then slumped by 565bps in 2022.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Gross Margin (Quarterly) stood at 95.79% in 2021, then plummeted by 94bps to 94.85% in 2022, then tumbled by 431bps to 90.54% in 2023, then slumped by 79bps to 89.75% in 2024, then plummeted by 243bps to 82.50% in 2025.
  • Its Gross Margin stands at 82.50% for Q3 2025, versus 86.18% for Q2 2025 and 79.42% for Q1 2025.